Compare Dollar Tree, Inc. (DLTR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Merck & Co., Inc. — how do they compare? Dollar Tree, Inc. trades at $127.1 (market cap $23.94B), while Merck & Co., Inc. trades at $123.59 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 12.5× Dollar Tree, Inc.'s market cap, and Merck & Co., Inc. pays a 2.82% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| DLTR | MRK | |
|---|---|---|
Market Cap | $23.94B | $298.31B |
Sector | Health | Health |
52-Week High | $141.21 | $129.52 |
52-Week Low | $85.04 | $77.60 |
Enterprise Value | $30.52B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $126.38, up 1.18% today, with a bullish technical signal and strong recent earnings beats. The company's fundamentals show a net loss in 2025 but improving cash flow and a $2.5 billion share repurchase authorization signal confidence. Analyst consensus is a Buy with a $131 price target, though valuation ratios like P/E of 20.29 and P/B of 6.93 reflect moderate pricing.
The outlook is positive due to earnings momentum and cost controls, but risks include traffic softness and tariff pressures. Upside potential exists if margin gains and multi-price strategy sustain growth, yet investors must weigh high debt and competitive headwinds against cash flow strength and institutional support.
Merck (MRK) trades at $123.6, down 0.35% today, with a bullish technical signal and strong institutional interest. Recent earnings have consistently beaten estimates, including Q1 2026, and the company is acquiring Terns Pharmaceuticals to bolster its oncology pipeline. The stock shows robust profitability with a net income margin of 28.07% in 2025 and a consensus analyst price target of $137.30, indicating potential upside.
The outlook remains positive due to earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Investors should weigh the strong analyst buy consensus against execution risks in integrating new assets and macroeconomic uncertainties affecting the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
